6-K 1 a0166u.htm DIRECTOR/PDMR SHAREHOLDING a0166u
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐                        
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
05 August 2025 - “Director/PDMR Shareholding”
 
 
 
 
99.1
 
 
 
 
 
​Haleon plc: Director/PDMR Shareholding 
​ 
5 August 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
 
On 1 August 2025, Ed Petter, Chief Corporate Affairs Officer, received the vesting of the second tranche of an award of Haleon Ordinary Shares under the Haleon Share Value Plan. The award was granted as part of his remuneration arrangements upon joining Haleon, to compensate for forfeited incentives from his previous employment.
 
The award is subject to malus and clawback provisions.
 
Further details are set out in the below notification, made in accordance with the requirements of The UK Market Abuse Regulations. 
 
1  
 
Details of the person discharging managerial responsibilities / person closely associated  
 
a)  
 
Name  
 
Ed Petter
2  
 
Reason for the notification  
 
a)  
 
Position/status  
 
 
Chief Corporate Affairs Officer
b)  
 
Initial notification /Amendment 
Initial Notification 
3  
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
a)  
 
Name  
 
Haleon plc 
b)  
 
LEI  
 
549300PSB3WWEODCUP19 
4  
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
a)  
 
Description of the financial instrument, type of instrument  
Ordinary Shares of £0.01 each
 
 
Identification code  
GB00BMX86B70   
 
 
b)  
 
Nature of the transaction  
 
Acquisition of Ordinary Shares in respect of a vesting of the Haleon plc Share Value Plan (Buyout award).
 
c)  
 
Price(s) and volume(s)  
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
Nil
112,924
 
 
 
 
 
d)  
 
Aggregated information
  
- Aggregated volume
 
- Price 
 
 
 
N/A
e)  
 
Date of the transaction  
 
1 August 2025
f)  
 
Place of the transaction  
 
Outside a trading venue
 
4  
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
a)  
 
Description of the financial instrument, type of instrument  
Ordinary Shares of £0.01 each
 
 
Identification code  
GB00BMX86B70   
 
 
b)  
 
Nature of the transaction  
 
Automatic disposal of Ordinary Shares resulting from Haleon plc Share Value Plan (Buyout award) vesting to cover tax liabilities.
 
c)  
 
Price(s) and volume(s)  
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
£3.639
53207.298246
 
 
 
 
 
d)  
 
Aggregated information
  
- Aggregated volume 
 
- Price 
 
 
 
N/A
e)  
 
Date of the transaction  
 
1 August 2025
f)  
 
Place of the transaction  
 
London Stock Exchange (XLON) 
 
 
 
Amanda Mellor
Company Secretary
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com. 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: August 05, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary